Dr. Sabatine and colleagues reply

New England Journal of Medicine

Volumn 373, Issue 8, 2015, Pages 774-775

  Sabatine, Marc S ^a   Wasserman, Scott M ^b   Stein, Evan A ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b AMGEN INC   (United States)

^c Metabolic and Atherosclerosis Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVOLOCUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY;

CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; BLOOD; CARDIOVASCULAR DISEASES; FEMALE; HYPERCHOLESTEROLEMIA; MALE;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE;

EID: 84939795885     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1508222     Document Type: Letter

References (13)

1. JG Robinson M Farnier M Krempf Efficacy and safety of alirocumab in reducing lipids and cardiovascular events N Engl J Med 372 2015 1489 1499
2. NJ Stone JG Robinson AH Lichtenstein 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2889 2934
3. H Schuster PJ Barter S Stender Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study Am Heart J 147 2004 705 713
4. EJ Mills C O'Regan O Eyawo Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40000 patients Eur Heart J 32 2011 1409 1415
5. Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
6. MS Sabatine RP Giugliano SD Wiviott Efficacy and safety of evolocumab in reducing lipids and cardiovascular events N Engl J Med 372 2015 1500 1509
7. E Stroes D Colquhoun D Sullivan Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab J Am Coll Cardiol 63 2014 2541 2548
8. DJ Blom T Hala M Bolognese A 52-week placebo-controlled trial of evolocumab in hyperlipidemia N Engl J Med 370 2014 1809 1819
9. FJ Raal EA Stein R Dufour PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Lancet 385 2015 331 340
10. NJ Stone JG Robinson AH Lichtenstein 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2889 2934
11. F Rodriguez T Olufade K Heithoff HS Friedman P Navaratnam JM Foody Frequency of high-risk patients not receiving high-potency statin (from a large managed care database) Am J Cardiol 115 2015 190 195
12. JP Halcox F Tubach E Lopez-Garcia Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe PLoS One 10 2015 e0115270
13. Sanofi/Regeneron. ODYSSEY outcomes: evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab SAR236553 (REGN727). ClinicalTrials.gov no. NCT01663402 https://clinicaltrials.gov/ct2/show/NCT01663402 July 2015